Prognosis analysis by involvement patterns
| . | . | N (%) . | 5-y OS . | 10-y OS . | P value (vs stage I) . | SMR . | P value for SMR . |
|---|---|---|---|---|---|---|---|
| Stage I | One lesion | 375 (63.2) | 91.4 (88.3-84.5) | 77.7 (72.5-83.3) | Ref. | 1.18 (0.94-1.49) | .156 |
| Stage I | Multifocal involvement of a single/pared extranodal site | 13 (2.2) | 80.0 (58.7-100) | 80.0 (58.7-100) | .457 | 0.94 (0.23-3.74) | .925 |
| Stage II | One site + regional LN(s) | 38 (6.4) | 85.9 (75.2-98.2) | 71.6 (57.2-89.6) | .041 | 1.48 (0.84-2.60) | .178 |
| Stage IV | Multiple distant skin involvement | 51 (8.6) | 95.6 (89.9-100) | 71.8 (58.1-88.8) | .852 | 1.46 (0.81-2.64) | .207 |
| Stage IV | Bilateral lung involvement | 17 (2.9) | 76.0 (58.0-99.6) | 43.2 (20.5-91.0) | .002 | 3.78 (1.89-7.76) | <.001 |
| Stage IV | One site + distant LN(s) | 36 (6.1) | 90.8 (81.3-100) | 67.6 (51.9-88.0) | .175 | 1.48 (0.80-2.75) | .216 |
| Stage IV | Multiple sites | 35 (5.9) | 79.5 (67.0-94.3) | 73.5 (60.0-90.0) | .038 | 2.31 (1.34-3.98) | .003 |
| Stage IV | Multiple sites + LN(s) | 28 (4.7) | 85.1 (72.6-99.7) | 67.7 (51.3-89.2) | .056 | 2.32 (1.21-4.46) | .012 |
| . | . | N (%) . | 5-y OS . | 10-y OS . | P value (vs stage I) . | SMR . | P value for SMR . |
|---|---|---|---|---|---|---|---|
| Stage I | One lesion | 375 (63.2) | 91.4 (88.3-84.5) | 77.7 (72.5-83.3) | Ref. | 1.18 (0.94-1.49) | .156 |
| Stage I | Multifocal involvement of a single/pared extranodal site | 13 (2.2) | 80.0 (58.7-100) | 80.0 (58.7-100) | .457 | 0.94 (0.23-3.74) | .925 |
| Stage II | One site + regional LN(s) | 38 (6.4) | 85.9 (75.2-98.2) | 71.6 (57.2-89.6) | .041 | 1.48 (0.84-2.60) | .178 |
| Stage IV | Multiple distant skin involvement | 51 (8.6) | 95.6 (89.9-100) | 71.8 (58.1-88.8) | .852 | 1.46 (0.81-2.64) | .207 |
| Stage IV | Bilateral lung involvement | 17 (2.9) | 76.0 (58.0-99.6) | 43.2 (20.5-91.0) | .002 | 3.78 (1.89-7.76) | <.001 |
| Stage IV | One site + distant LN(s) | 36 (6.1) | 90.8 (81.3-100) | 67.6 (51.9-88.0) | .175 | 1.48 (0.80-2.75) | .216 |
| Stage IV | Multiple sites | 35 (5.9) | 79.5 (67.0-94.3) | 73.5 (60.0-90.0) | .038 | 2.31 (1.34-3.98) | .003 |
| Stage IV | Multiple sites + LN(s) | 28 (4.7) | 85.1 (72.6-99.7) | 67.7 (51.3-89.2) | .056 | 2.32 (1.21-4.46) | .012 |
LN, lymph node.